Step 1 of 2
Downloadable slides on the clinical application and safety management of CD19- and BCMA-directed CAR T-cell therapies in hematologic malignancies, with a focus on recognizing and managing acute, delayed, and long-term toxicities in community and shared-care settings. The slides review pivotal clinical trial data supporting approved CAR T-cell therapies for acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma, along with evidence-based strategies for identifying and managing cytokine release syndrome, immune effector cell–associated neurotoxicity syndrome, prolonged cytopenias, infections, hypogammaglobulinemia, and delayed neurologic complications. Practical guidance on toxicity monitoring, infection prevention, vaccination, supportive care, patient and caregiver education, and coordination between cellular therapy centers and community oncology teams supports timely intervention and continuity of care following CAR T-cell therapy.